December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

35.24 +0.30 (+0.86%)
Streaming Delayed Price Updated: 9:57 AM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,637
Open 35.08
Bid (Size) 35.17 (3)
Ask (Size) 35.59 (1)
Prev. Close 34.94
Today's Range 35.05 - 36.39
52wk Range 13.37 - 40.16
Shares Outstanding 60,648,883
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in generalized... 
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga

Performance

YTD
+51.9%
+51.9%
1 Month
+33.0%
+33.0%
3 Month
+93.1%
+93.1%
6 Month
+125.8%
+125.8%
1 Year
+33.1%
+33.1%

More News

Read More
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
Via Benzinga
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Analyst Expectations For Dianthus Therapeutics's Future
Via Benzinga
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
Via Investor's Business Daily
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline
Via Benzinga
Top movers in Monday's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
The Oncology Institute Announces Changes to Board of Directors
From Toi Management, LLC
Via GlobeNewswire
Dianthus Therapeutics Inc (NASDAQ:DNTH) Q2 2025 Earnings: Revenue Misses, EPS Meets Estimates
Via Chartmill
Dianthus (DNTH) Q2 Loss Widens 80%
Via The Motley Fool
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Friday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga

Frequently Asked Questions

Is Dianthus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dianthus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dianthus Therapeutics, Inc. - Common Stock trade on?
Dianthus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dianthus Therapeutics, Inc. - Common Stock?
The ticker symbol for Dianthus Therapeutics, Inc. - Common Stock is DNTH on the Nasdaq Stock Market
What is the current price of Dianthus Therapeutics, Inc. - Common Stock?
The current price of Dianthus Therapeutics, Inc. - Common Stock is 35.24
When was Dianthus Therapeutics, Inc. - Common Stock last traded?
The last trade of Dianthus Therapeutics, Inc. - Common Stock was at 10/06/25 09:57 AM ET
What is the market capitalization of Dianthus Therapeutics, Inc. - Common Stock?
The market capitalization of Dianthus Therapeutics, Inc. - Common Stock is 2.14B
How many shares of Dianthus Therapeutics, Inc. - Common Stock are outstanding?
Dianthus Therapeutics, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.